Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA: 36 Dead From Breast Implant-Associated Lymphoma Since 2019, Hundreds Sickened

Agency also verifies Breast-Q module as a tool to help assess women's satisfaction with implanted devices

Executive Summary

The US FDA reports the numbers on women globally who've died or been sickened by two types of breast implant illnesses.

You may also be interested in...



Worldwide Recall On Allergan Textured Breast Implants

Allergan PLC announced that it would take its Biocell textured breast implants and tissue expanders off the market worldwide shortly after the US FDA released additional information linking the use of the implants to a rare cancer.

'Do Your Job': To The Dismay Of Patients, FDA Panelists On Breast Implants Advise Better Risk Warnings, Not Recalls

Despite pleas from breast implant patients at a March 25-26 US FDA advisory committee meeting for the agency to take off the market silicone and saline breast implants that have initiated a serious range of symptoms in some women, the panel instead recommended FDA get out stronger public advisories warning of the risks of breast implants and a lymphoma associated with the products.

Cases Of Rare Lymphoma Linked To Breast Implants Increase

US FDA is now aware of 414 cases of breast implant-associated anaplastic large cell lymphoma. The agency says that updated medical literature estimates of the lifetime risk of textured breast implanted patients developing BIA-ALCL range between 1 in 3,817 to 1 in 30,000.

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel